» Articles » PMID: 38407228

REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer

Overview
Journal Ann Surg
Specialty General Surgery
Date 2024 Feb 26
PMID 38407228
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The REDISCOVER consensus conference aimed at developing and validating guidelines on the perioperative care of patients with borderline-resectable (BR-) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).

Background: Coupled with improvements in chemotherapy and radiation, the contemporary approach to pancreatic surgery supports the resection of BR-PDAC and, to a lesser extent, LA-PDAC. Guidelines outlining the selection and perioperative care for these patients are lacking.

Methods: The Scottish Intercollegiate Guidelines Network (SIGN) methodology was used to develop the REDISCOVER guidelines and create recommendations. The Delphi approach was used to reach a consensus (agreement ≥80%) among experts. Recommendations were approved after a debate and vote among international experts in pancreatic surgery and pancreatic cancer management. A Validation Committee used the AGREE II-GRS tool to assess the methodological quality of the guidelines. Moreover, an independent multidisciplinary advisory group revised the statements to ensure adherence to nonsurgical guidelines.

Results: Overall, 34 recommendations were created targeting centralization, training, staging, patient selection for surgery, possibility of surgery in uncommon scenarios, timing of surgery, avoidance of vascular reconstruction, details of vascular resection/reconstruction, arterial divestment, frozen section histology of perivascular tissue, extent of lymphadenectomy, anticoagulation prophylaxis, and role of minimally invasive surgery. The level of evidence was however low for 29 of 34 clinical questions. Participants agreed that the most conducive means to promptly advance our understanding in this field is to establish an international registry addressing this patient population ( https://rediscover.unipi.it/ ).

Conclusions: The REDISCOVER guidelines provide clinical recommendations pertaining to pancreatectomy with vascular resection for patients with BR-PDAC and LA-PDAC, and serve as the basis of a new international registry for this patient population.

Citing Articles

Robotic Distal Pancreatectomy with Celiac Axis Resection and SMA Divestment: A Step-by-Step Educational Video.

Garnier J, Javed A, Sacks G, Marchetti A, Andel P, Garg K Ann Surg Oncol. 2025; .

PMID: 39918751 DOI: 10.1245/s10434-025-16943-4.


3D modeling to predict vascular involvement in resectable pancreatic adenocarcinoma.

R S, J V, F P, DA B, A L, E G Heliyon. 2025; 11(1):e41473.

PMID: 39850404 PMC: 11754173. DOI: 10.1016/j.heliyon.2024.e41473.


Total Pancreatectomy for Locally Advanced Pancreatic Adenocarcinoma with Coeliac Trunk Resection and Retrograde Gastric Revascularization Through Aorto-Hepato-Spleno Allograft.

Touzmanian J, Morel Y, Aussilhou B, Lesurtel M, Sauvanet A, Dokmak S Ann Surg Oncol. 2025; 32(4):2852-2853.

PMID: 39821544 DOI: 10.1245/s10434-024-16844-y.


[Evidence for the extent and oncological benefit of lymphadenectomy for pancreatic cancer].

Keck T Chirurgie (Heidelb). 2025; .

PMID: 39820664 DOI: 10.1007/s00104-024-02219-2.


ASO Author Reflections: Should We Resect the "Unresectable"? Since Alexis Carrel and Joseph G. Fortner, Almost 120 Years of (Pancreatic) Vascular Surgery in New York.

Garnier J, Wolfgang C Ann Surg Oncol. 2025; 32(4):2491-2492.

PMID: 39755891 DOI: 10.1245/s10434-024-16826-0.


References
1.
Conroy T, Pfeiffer P, Vilgrain V, Lamarca A, Seufferlein T, OReilly E . Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(11):987-1002. DOI: 10.1016/j.annonc.2023.08.009. View

2.
Isaji S, Mizuno S, Windsor J, Bassi C, Fernandez-Del Castillo C, Hackert T . International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2017; 18(1):2-11. DOI: 10.1016/j.pan.2017.11.011. View

3.
Giannone F, Capretti G, Abu Hilal M, Boggi U, Campra D, Cappelli C . Resectability of Pancreatic Cancer Is in the Eye of the Observer: A Multicenter, Blinded, Prospective Assessment of Interobserver Agreement on NCCN Resectability Status Criteria. Ann Surg Open. 2023; 2(3):e087. PMC: 10455302. DOI: 10.1097/AS9.0000000000000087. View

4.
van der Geest L, van Rijssen L, Molenaar I, de Hingh I, Groot Koerkamp B, Busch O . Volume-outcome relationships in pancreatoduodenectomy for cancer. HPB (Oxford). 2016; 18(4):317-24. PMC: 4814615. DOI: 10.1016/j.hpb.2016.01.515. View

5.
Maggino L, Malleo G, Marchegiani G, Viviani E, Nessi C, Ciprani D . Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2019; 154(10):932-942. PMC: 6659151. DOI: 10.1001/jamasurg.2019.2277. View